Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2009 Feb;10(3):353-67. doi: 10.1517/14656560802694655 .

Pharmacotherapy of patients with schizophrenia and substance abuse.

Author information

  • 1Georg-August-University, Department of Psychiatry and Psychotherapy, Von-Siebold Strasse 5, D-37075 Göttingen, Germany.

Abstract

BACKGROUND:

Comorbid substance-use disorder in schizophrenia patients is associated with poor clinical and functional outcome.

OBJECTIVE:

To provide evidence-based pharmacological treatment recommendations to improve the disease course of this patient group.

METHODS:

A comprehensive systematic review of the pharmacological studies in this subgroup of patients was performed and the available studies were discussed from the standpoint of evidence-based medicine.

RESULTS/CONCLUSION:

Slight advantages were found for second-generation antipsychotic agents over conventional antipsychotics with regard to improvement of distinct psychopathological symptoms, reduced craving, and greater reduction of substance use; these findings are mainly derived from open studies or case series. Additional treatment with antidepressants, depending on the patient's psychopathology, as well as with anti-craving agents should be considered.

PMID:
19191675
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Write to the Help Desk